🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for R/R AML

Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia NCT07144020EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: CD117 CAR T-cells A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT05924750Phase 18 sites📍 Hefei📍 Beijing📍 Haerbin Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M11D1 Off-the-shelf CD123 CAR-NK for R/R AML NCT06201247EARLY Phase 11 site📍 Beijing Peking University People's Hospital · Tests: JD123 injection Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS NCT06680752Phase 1, Phase 23 sites📍 Charlotte📍 Winston-Salem📍 Houston ARCE Therapeutics, Inc. · Tests: ARD103, Cyclophosphamide, Fludarabine Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML NCT05305859Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: venetoclax combining chidamide and azacitidine (VCA) Study of IBR733 Cell Injection in Acute Myeloid Leukemia NCT06234904Phase 11 site📍 Suzhou Imbioray (Hangzhou) Biomedicine Co., Ltd. · Tests: IBR733 Cell Injection HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML NCT06594445Phase 11 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: GTB-360 A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS NCT06731699Phase 11 site📍 Chengdu Chengdu FenDi Pharmaceutical Co., Ltd. · Tests: FD-001 A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML NCT05735184Phase 144 sites📍 Phoenix📍 La Jolla📍 Los Angeles Kura Oncology, Inc. · Tests: Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia NCT06613217Phase 11 site📍 Houston Pacylex Pharmaceuticals · Tests: zelenirstat First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) NCT07384715Phase 16 sites📍 Aarhus📍 Copenhagen📍 Barcelona Genmab · Tests: GEN3018 A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome NCT06501196Phase 113 sites📍 Duarte📍 Los Angeles📍 Palo Alto BlossomHill Therapeutics · Tests: BH-30236, Venetoclax Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... NCT02390752Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: TURALIO(R) Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS NCT06846606Phase 19 sites📍 Duarte📍 Tampa📍 Buffalo Auron Therapeutics, Inc. · Tests: AUTX-703 Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML NCT06737523Phase 11 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: CVA CD123-CD16-NK Cells Immunotherapy for AML NCT06835140Phase 11 site📍 Beijing Chunji Gao · Tests: Donor-derived CD123-CD16 bispecific antibody-modified NK cells Tazemetostat and Palbociclib With CPX-351for R/R AML NCT05627232Phase 11 site📍 Philadelphia Thomas Jefferson University · Tests: Tazemetostat, Liposome-encapsulated Daunorubicin-Cytarabine, Bone Marrow Aspiration and Biopsy, Biospecimen Collection,… Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML NCT07617285Phase 11 site📍 Beijing Peking University People's Hospital · Tests: CAR-T cells chimeric antigen receptor T cells HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML NCT05586074Phase 31 site📍 Hanzhou Sunshine Lake Pharma Co., Ltd. · Tests: Clifutinib, LoDAC, Azacitidine, Decitabine, Ara-C±IDA Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia NCT07263906Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Anti-LILRA6 CAR-T cells Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion) NCT05949125Phase 115 sites📍 Ulm📍 Munich📍 Würzburg AvenCell Europe GmbH · Tests: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123, Allo-RevCAR01-T CAV Regimen for R/R AML NCT05657639Phase 21 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: CAV Regimen, MEC Regimen A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients NCT07500753NA1 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Allogeneic Hematopoietic Stem Cell Transplantation Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML NCT06741722Phase 21 site📍 Beijing Beijing 302 Hospital · Tests: Decitabine, Azacitidine, Mitoxantrone liposome, Cytarabine, G-CSF A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia NCT06387069Phase 353 sites📍 Hefei📍 Hefei📍 Hefei Hutchmed · Tests: HMPL-306 Regimen, Salvage Chemotherapy Regimen A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation NCT04065399Phase 1, Phase 257 sites📍 Duarte📍 Los Angeles📍 Palo Alto Syndax Pharmaceuticals · Tests: revumenib, cobicistat Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia NCT07668557Phase 12 sites📍 Nanchang📍 Nanchang iCell Gene Therapeutics · Tests: Anti-CD33-CLL1 CAR-T cells (ICG415) following lymphodepleting fludarabine and cyclophosphamide Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML NCT07007312Phase 3136 sites📍 Gilbert📍 Clovis📍 La Jolla Kura Oncology, Inc. · Tests: Ziftomenib, Placebo, Venetoclax, Azacitidine (AZA), Daunorubicin BCL2i CLAG-M in R/R Acute Myeloid Leukemia NCT06660368Phase 22 sites📍 Tampa📍 Boston H. Lee Moffitt Cancer Center and Research Institute · Tests: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Venetoclax Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN NCT07710534Phase 21 site📍 Richmond Virginia Commonwealth University · Tests: Decitabine-cedazuridine plus venetoclax (DEC-C+VEN), Azacitidine plus venetoclax (AZA+VEN)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy